<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.nitrc.org/themes/nitrc3.0/css/rss.xsl.php?feed=https://www.nitrc.org/export/rss20_forum.php?forum_id=4778" ?>
<?xml-stylesheet type="text/css" href="https://www.nitrc.org/themes/nitrc3.0/css/rss.css" ?>
<rss version="2.0"> <channel>
  <title>NITRC News Group Forum: erotic-stimulus-processing-under-amisulpride-and-reboxetine--a-placebo-controlled-fmri-study-in-healthy-subjects.</title>
  <link>http://www.nitrc.org/forum/forum.php?forum_id=4778</link>
  <description>
	&lt;table border=&quot;0&quot; width=&quot;100%&quot;&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;/&gt;&lt;/tr&gt;&lt;/table&gt;
        &lt;p&gt;&lt;b&gt;Erotic Stimulus Processing under Amisulpride and Reboxetine: A Placebo-Controlled fMRI Study in Healthy Subjects.&lt;/b&gt;&lt;/p&gt;          
        &lt;p&gt;Int J Neuropsychopharmacol. 2014 Oct 31;&lt;/p&gt;
        &lt;p&gt;Authors:  Graf H, Wiegers M, Metzger CD, Walter M, Grön G, Abler B&lt;/p&gt;
        &lt;p&gt;Abstract&lt;br/&gt;
        BACKGROUND: Impaired sexual function is increasingly recognized as a side effect of psychopharmacological treatment. However, underlying mechanisms of action of the different drugs on sexual processing are still to be explored. Using functional magnetic resonance imaging, we previously investigated effects of serotonergic (paroxetine) and dopaminergic (bupropion) antidepressants on sexual functioning (Abler et al., 2011). Here, we studied the impact of noradrenergic and antidopaminergic medication on neural correlates of visual sexual stimulation in a new sample of subjects.&lt;br/&gt;
        METHODS: Nineteen healthy heterosexual males (mean age 24 years, SD 3.1) under subchronic intake (7 days) of the noradrenergic agent reboxetine (4mg/d), the antidopaminergic agent amisulpride (200mg/d), and placebo were included and studied with functional magnetic resonance imaging within a randomized, double-blind, placebo-controlled, within-subjects design during an established erotic video-clip task. Subjective sexual functioning was assessed using the Massachusetts General Hospital-Sexual Functioning Questionnaire.&lt;br/&gt;
        RESULTS: Relative to placebo, subjective sexual functioning was attenuated under reboxetine along with diminished neural activations within the caudate nucleus. Altered neural activations correlated with decreased sexual interest. Under amisulpride, neural activations and subjective sexual functioning remained unchanged.&lt;br/&gt;
        CONCLUSIONS: In line with previous interpretations of the role of the caudate nucleus in the context of primary reward processing, attenuated caudate activation may reflect detrimental effects on motivational aspects of erotic stimulus processing under noradrenergic agents.&lt;br/&gt;
        &lt;/p&gt;&lt;p&gt;PMID: 25612894 [PubMed - as supplied by publisher]&lt;/p&gt;
    </description>
  <language>en-us</language>
  <copyright>Copyright 2000-2026 NITRC OSI</copyright>
  <webMaster></webMaster>
  <lastBuildDate>Fri, 01 May 2026 17:27:52 GMT</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <generator>NITRC RSS generator</generator>
 </channel>
</rss>
